Applied Therapeutics said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after ...

Applied Therapeutics' New Drug Application for a rare metabolic disease was rejected by the Food and Drug Administration, ...

Applied Therapeutics stock (APLT) was down 75% early Friday on news the FDA had declined to approve its drug govorestat, ...

Applied Therapeutics said on Wednesday that the U.S. FDA declined to approve its drug to treat galactosemia, a rare genetic ...

Fintel reports that on December 2, 2024, UBS downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) from Buy to ...

The pharma company's shares are getting crushed after regulators decline to green light a drug to treat a rare disease.

Applied Therapeutics faces challenges after FDA rejection, but future opportunities exist. Learn why APLT stock could recover ...

After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ ...

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on APLT stock, giving a Buy rating on November 29.Don't Miss our ...

UBS analyst Colin Bristow downgraded Applied Therapeutics (APLT) to Neutral from Buy with a price target of $2, down from $13.Don't Miss our ...

FDA rejected Applied Therapeutics' Govorestat for galactosemia, citing NDA deficiencies. The company plans discussions for ...

The US Food and Drug Administration has declined to approve Applied Therapeutics’ govorestat for classic galactosemia.